TLR4 and Parkinson disease: In the central nervous system, systemic LPS injection initiates the acute phase response and upregulates membrane CD14 receptor that controls TLR4 endocytosis [59,113] and induces microglial activation that results in neurodegeneration and Parkinson’s disease (PD) [114].